Background. Rodent models that accurately reflect human filovirus infection are needed as early screens for medical countermeasures. Prior work in rodents with the Zaire species of Ebola virus (ZEBOV) primarily used inbred mice and guinea pigs to model disease. However, these inbred species do not show some of the important features of primate ZEBOV infection, most notably, coagulation abnormalities.
this writing, this outbreak has resulted in >50 times more human infections than any known past outbreak, with >21 000 cases and an estimated mortality of 50% [2] . Historically, filovirus outbreaks have remained relatively isolated to remote areas of Central Africa, which has likely contributed to the relatively rapid success in controlling spread. Conversely, the current outbreak is in a geographically connected, more-densely populated, and highly transient population, making this outbreak more of a global concern than ever before [3] .
Development of countermeasures against filovirus infections has depended on the use of mice [4, 5] , hamsters [6] , and various strains of guinea pigs [7] [8] [9] as rodent models for screening prior to preclinical evaluation in the gold standard NHP models of filovirus infection [10, 11] . All filovirus rodent models have required adaptation prior to reaching uniformly lethality, whereas NHP models do not. Few of these small-animal models have recapitulated hallmark features of the disease course seen in humans or NHP, specifically the induction of coagulopathies and vascular leak syndromes. Importantly, few have demonstrated a consistent predictive value for any potential countermeasures against lethal filovirus challenge in NHPs.
The guinea pig and hamster are the only rodent models that currently use outbred animals presenting with coagulopathies more reflective of those seen in NHPs and humans. The hamster model is a relatively new model, and its predictive value has yet to be determined. Conversely, the guinea pig model has shown some success in predicting the efficacy of therapies, including small interfering RNA [12, 13] and antibody-based therapies [14, 15] , in NHPs. Although some countermeasures have shown efficacy in mice, they unfortunately do not all correlate to efficacy in NHPs [16] . The reason for differences in the predictive value between rodent models of filovirus disease is unclear.
Detailed descriptions of EHF progression in guinea pigs to date have primarily used strain 13 guinea pigs [7] . While useful as an early model of EHF, this inbred guinea pig strain has demonstrated altered immune responsiveness and thus may not be representative of the heterogeneous immune responses of outbred hosts such as NHPs and humans [17, 18] . Further, the availability of this variety of guinea pig is limited, as very few breeding colonies exist. To address this concern, we have developed a uniformly lethal model of EHF in outbred guinea pigs. We performed a temporal study to detail the events leading to death in ZEBOV-infected outbred guinea pigs and show that many of the hallmark features of EHF in humans and NHP are represented. To date, all filovirus rodent models have required genetic changes that ultimately have resulted in changes of 1 or more viral proteins. We also provide comparative sequence analysis that identifies mutations that resulted from serial passage in guinea pigs and/or cell culture.
MATERIALS AND METHODS

Virus Adaptation
The starting material for adaptation was serum from Mayinga N'Seka, a nurse who died during the original outbreak of ZEBOV in 1976 in the country formerly known as Zaire [19] . The serum was amplified by 1 passage in Vero 76 cells (ATCC CRL-1587, ATCC). A group of inbred strain 13 guinea pigs was then challenged by intramuscular injection with approximately 6000 plaque-forming units (PFU) of the Vero culture fluid containing ZEBOV. Spleens from 2 animals were collected at day 7 after infection. Another group of inbred strain 13 guinea pigs was then challenged by intramuscular injection with approximately 6000 PFU of the pooled clarified 10% spleen homogenates from these 2 animals. This process was repeated for a total of 4 passages until uniform lethality was achieved in the inbred strain 13 guinea pigs. This Vero p1, inbred strain 13 guinea pig spleen p4 material was then amplified by 1 passage in Vero 76 cells. A group of outbred Hartley strain guinea pigs were then challenged by intraperitoneal injection with approximately 100 PFU of the Vero culture fluid containing the inbred strain 13 guinea pig adapted ZEBOV. Liver and spleen from one of these animals was harvested at day 7 after infection. Another group of inbred strain 13 guinea pigs was then challenged by intraperitoneal injection with approximately 50 PFU of the pooled clarified 10% liver and spleen homogenate from this animal. This process was repeated for a total of 3 passages until uniform lethality was achieved in the outbred Hartley strain guinea pigs. This Vero p1, inbred strain 13 guinea pig spleen p4, Vero p1, outbred guinea pig liver plus spleen p3 material was then amplified by 1 passage in Vero 76 cells to produce a seed stock. This seed stock produced uniform lethality in 18 of 18 outbred Hartley strain guinea pigs when animals were challenged by intraperitoneal injection with approximately 5000 PFU of the virus stock.
Animal Inoculation
Animal studies were completed under biosafety level 4 (BSL-4) biocontainment at the Galveston National Laboratory and were approved by the University of Texas Medical Branch Institutional Laboratory Animal Care and Use Committee, in accordance with state and federal statutes and regulations relating to experiments involving animals, and the University of Texas Medical Branch Institutional Biosafety Committee. Female outbred Hartley strain guinea pigs (weight, approximately 351-400 g; age, approximately 5-6 weeks) were acclimatized for approximately 1 week prior to ZEBOV challenge. Thirty-six animals were divided into 9 groups of 4 animals per group (8 experimental groups and 1 control group). Individual animals were infected with approximately 5000 PFU in 0.5 mL of guinea pig-adapted ZEBOV-Mayinga or mock infected (using Hank's balanced salt solution with 2% fetal bovine serum) by intraperitoneal injection.
Necropsy
Guinea pigs from each ZEBOV-infected experimental group of animals was euthanized daily for 8 days after infection or when indicated by protocol euthanasia criteria (n = 4/group/day). This terminal time point shall hereafter be referred to as terminus. Clinical signs, weights, and transponder-mediated temperatures were recorded daily up to the point of euthanasia. Prior to necropsy, whole-blood specimens, plasma specimens (collected in tubes containing ethylenediaminetetraacetic acid), and citrated plasma samples were collected by cardiac puncture for hematologic analysis, a serum/plasma biochemical assay, and viremia determination. Gross pathology findings were documented, and portions of select tissues were aseptically removed and frozen at −70°C for virus infectivity assays. The following tissues were collected on all animals for histologic and immunohistochemical analyses: liver, spleen, kidney, adrenal gland, lung, brain, lymph nodes (axillary, inguinal, mesenteric, and mandibular), salivary gland, trachea, esophagus, stomach, duodenum, ileocecal junction, colon, urinary bladder, reproductive tract, pancreas, haired skin, and heart.
Histologic and Immunohistochemical Analyses
Selected tissues were fixed in formalin for at least 21 days in the BSL-4 facility. Specimens were then removed from the BSL-4 facility, processed in a BSL-2 facility by using conventional procedures, and embedded in paraffin for sectioning for histopathologic analysis as outlined in the Supplementary Materials.
Hematologic Analysis, Serum Biochemistry Analysis, Measurement of Proinflammatory Markers, and Determination of Coagulation Parameters
Complete blood counts, coagulation dynamics, and serum analysis of blood chemistry were performed on blood, serum, or plasma specimens collected from each experimental animal. Analyses of select cytokines, coagulation factors, eicanosoids, and nitric oxide measured in serum or plasma specimens were also performed as detailed in the Supplementary Materials.
Virus Isolation
Determination of infectious virus in plasma, spleen, liver, kidney, adrenal gland, pancreas, lung, and brain was performed using standard plaque assays as outlined in the Supplementary Materials.
Statistics Statement
Conducting animal studies in a BSL-4 facility severely restricts the number of animal subjects, the volume of biological samples that can be obtained, and the ability to repeat assays independently and thus limits the power of statistical analyses. Consequently, data are presented as the mean values calculated from replicate samples, not replicate assays, and error bars represent the standard deviation across replicates.
RESULTS
Virus Adaptation and Sequence Analysis
Sequence comparison of guinea pig-adapted ZEBOV-Mayinga with the prototype sequence (accession number AF086833.2) revealed nucleotide substitutions that resulted in 2 amino acid changes in NP and single changes in VP40 and glycoprotein. Two amino acid changes in VP24 were also identified, of which the L26F mutation has previously been identified as sufficient to confer virulence in guinea pigs [20] (Table 1) . One nucleotide substitution was discovered in the noncoding region, and 1 silent mutation was identified in the gene encoding NP. The resulting mutations may have been acquired during the consecutive passages in guinea pigs and/or 2 passages in Vero 76 cells during seed production.
Virus Titers in Blood and Tissue Specimens
Plasma viremia was first detected on day 2 at 3.0 log 10 PFU/mL. Mean peak viremia of 5.3 log 10 PFU/mL was recorded on day 3 and maintained at elevated levels through the remaining time points. Infectious virus was recovered beginning on day 2 from all tissues except brain; recovery was negative for all time points at which brains were collected. Early in infection, spleens contained higher mean titers than other tissues, suggesting that spleen is likely an early site of infection, as previously reported [7, 21] . Mean infectivity titers in all organs steadily increased to peak levels on postinfection days 7 and 8 ( Table 2) .
Gross Pathology
No significant gross lesions were present in the mock-infected control guinea pigs ( Figure 1A ). Gross lesions present at necropsy of ZEBOV-infected guinea pigs began on day 3 and progressed in severity over the course of the study. The most significant gross lesions included splenic mottling with enlargement, hepatic reticulation with progressive pallor, lymphadenomegaly, interstitial pneumonia, multiorgan serosal and mucosal congestion and/or hemorrhage, and gastric ulceration ( Figure 1B-D) . See the Supplementary Materials for detailed gross pathology findings. Mean changes in weight and temperature were collected for control and terminal guinea pigs. Beginning on day 3, ZEBOVinfected guinea pigs had progressive weight loss (mean loss, up to 16% of body mass) and increases in body temperature (maintaining an average of 1°C greater than normal, followed rapidly by hypothermia). Control animals did not experience weight loss or changes in body temperature over the course of the study ( Figure 1E ).
Histopathologic and Immunohistochemical Findings
Histopathologic lesions and immunoreactivity for Ebola VP40 antigen among infected guinea pigs were most apparent by day 3, with the severity of lesions increasing over the duration of the study. No significant histopathologic lesions or immunoreactivity for Ebola antigen or fibrin was observed in any of the examined negative control guinea pig tissues.
Liver Ebola VP40 antigen-positive Kupffer cells were present on day 1 (2 of 4 animals) and 2 (4 of 4; Figure 2F ), yet no significant hepatocellular lesions were observed on hematoxylin-eosin (HE)-stained sections. Progressive hepatocellular vacuolation, degeneration/necrosis, and sinusoidal leukocytosis were D) . B, Gross lesions were noted in the following organs of ZEBOV-infected guinea pigs: liver (asterisk), diffuse pallor (hepatocellular degeneration/necrosis); lung (white arrow), petechiae, rib impressions, and failure to collapse (interstitial pneumonia); intestines (white arrow), flaccid with liquid contents; and colon and uterus (white arrow), multifocal serosal congestion. C, Gross lesions were noted in the stomach of ZEBOV-infected guinea pigs: serosal hemorrhage (white arrow) and mucosal ulceration (inset). D, Gross lesions were noted in and near the distal limb of ZEBOV-infected guinea pigs, as follows: subcutaneous tissues of the distal limb, locally extensive hemorrhage (#); and inguinal lymph node, hemorrhage (white arrow). E, Weight loss and temperature over the course of the study in ZEBOV-infected guinea pigs (solid red line and dotted red line, respectively) and control guinea pigs (solid black line and dotted black line, respectively).
observed on HE-stained sections in all animals (24 of 24) on days 3, 4, 5, 6, and 7 and at terminus ( Figure 2B-D) . Additionally, Councilman bodies and eosinophilic, intracytoplasmic viral inclusion bodies were present on day 4 through terminus (20 of 20 animals). Hepatocellular mineralization associated with regions of degeneration and necrosis was increasingly evident starting on day 5 through terminus (12 of 16 animals). All infected animals (24 of 24), starting at day 3 through terminus, had Ebola antigen in Kupffer cells and individualized hepatocytes with progressive coalescing clusters of positive hepatocytes ( Figure 2G-I) .
Spleen
Rare Ebola VP40 antigen-positive mononuclear cells within the red pulp were present on day 1 (4 of 4 animals; Figure 3B ), yet no significant lesions were observed on HE-stained sections. On day 2, increased numbers of EBOV-positive mononuclear cells were present in the red pulp, accompanied by hypercellularity and congestion (4 of 4 animals). At day 3, EBOV immunoreactivity peaked, with clusters of mononuclear cells present within the red and white pulp (4 of 4 animals; Figure 3E ). All animals (20 of 20), beginning on day 4 and continuing through day 8, had progressive lymphocyte depletion with tingible body macrophages within the white pulp and immunoreactive mononuclear cells that plateaued at day 4. TUNEL staining of apoptotic populations within the splenic germinal centers increased over time, with peak intensity at day 5 ( Figure 3I ). Positive immunoreactivity for fibrin was scattered throughout the red pulp and clustered within the marginal zone of the germinal centers in ZEBOV-infected guinea pigs ( Figure 4C ).
Lymphoid Tissues
Mononuclear cells positive for Ebola VP40 antigen were rare within the subcapsular and medullary sinuses of the mandibular lymph node and appeared on day 2 (2 of 4 animals), yet no significant lesions were observed on HE-stained sections. On day 3, immunoreactive mononuclear cells within the subcapsular and medullary sinuses of the mandibular, axillary, and inguinal lymph nodes (4 of 4, 1 of 4, and 4 of 4 animals, respectively) were present, with increased numbers of immunoreactive cells at day 4 through terminus in all animals (20 of 20) . Hemorrhage in the subcapsular and medullary sinuses was observed in inguinal lymph nodes on days 4 and 6 (2 of 4 and 2 of 4 animals, respectively). Lymphocyte degeneration and necrosis was observed in the mandibular lymph node on days 5, 6, and 7 and terminus (1 of 4, 1 of 4, 4 of 4, and 1 of 4 animals, respectively) and in the inguinal lymph node on day 7 and terminus (4 of 4 and 2 of 4, respectively). Ebola antigen-positive mononuclear cells within the medulla of the thymus were present starting on day 4 through terminus (17 of 20 animals). Beginning on day 6 and continuing through the study, clusters of immunoreactive interstitial cells of the salivary gland were present (1 of 2, 3 of 4, and 3 of 4 animals, respectively). No significant lesions were observed on HE-stained sections of axillary lymph node, thymus, and salivary gland. 
Adrenal Gland
Ebola VP40 antigen-positive stellate interstitial cells were first present within the medullary region, starting on day 3 (1 of 4 animals), and, by day 4 through terminus, were present within stellate interstitial cells of all regions of the adrenal gland and cortical cells (18 of 20) . This corresponded with cortical medullary hemorrhage, starting on day 3 through terminus (21 of 24 animals), and with cortical necrosis at terminus (4/4).
Gastrointestinal Tract
Ebola VP40 antigen in scattered mononuclear interstitial cells within the pancreas, often surrounding small vessels, was 
Urogenital Tract
Ebola VP40 antigen-positive mononuclear interstitial cells within the uterus, often surrounding small vessels, were present on day 3, with dispersion throughout the uterine stroma and, rarely, the glandular epithelium by terminus (21 of 24 animals; Supplementary Figure 1C) . No significant lesions were observed on HE-stained sections of uterus. This cell type was also found within the ovary in close proximity to surrounding small vessels, starting on day 3, and began progressively concentrating within follicular thecal cells by terminus (21 of 24 animals) . This corresponded to progressive degeneration and necrosis of thecal cells, starting at day 5 through terminus (20 of 20) .
Ebola antigen was also noted in scattered mononuclear interstitial cells within the renal pelvic subepithelial stroma on day 5 and began progressively concentrating on the pelvic transitional epithelium by terminus (19 of 20 animals; Supplementary Figure 1D ). This corresponded to minimal mixed inflammation infiltrates, starting at day 7 through terminus (8 of 8 animals). Similar inflammatory infiltrates and immunoreactivity was noted in mononuclear interstitial cells of the urinary bladder submucosa and transitional epithelium, starting at day 5 through terminus (19 of 20 animals; Supplementary Figure 1E ).
Brain
Positive immunoreactivity for Ebola VP40 antigen was noted in the endothelium lining the vessels of the choroid plexus, starting on day 5 through terminus (6 of 20 animals), yet no significant lesions were observed on HE-stained sections (data not shown).
Hematologic Findings
Total and differential white blood cell counts of ZEBOV-infected guinea pigs revealed strong evidence of neutrophilia-mediated leukocytosis. Markedly elevated levels of circulating neutrophils were noted beginning 1 day after infection and remained at high levels through the course of infection. A concurrent marked lymphopenia was observed, as evidenced by declining mean lymphocyte counts. Striking thrombocytopenia, evidenced by reduced circulating platelets, compared with control values, was marked beginning at day 4 and continuing through to terminal collection. Increases in mean platelet volume were also noted beginning on day 4 through terminal time points for both strains. Finally, increases in basophilic and eosinophilic granulocyte counts were observed beginning on day 4, and counts remained elevated through to terminal collection (Table 3) .
Serum Biochemistry Findings
No remarkable changes were noted in early serum liver-associated enzyme levels; but most all were elevated at late stage of disease (Table 3) . Beginning on day 4 and continuing to terminal time points, marked increases (by 2-5-fold) in aspartate aminotransferase levels were observed. No remarkable changes in alkaline phosphatase levels were detected until late in disease in which peak levels of alanine aminotransferase were also recorded. Total bilirubin levels were within normal limits up to day 6, when levels doubled and remained elevated to terminal collection. Blood urea nitrogen levels remained consistent until late in the disease course, when mean increases began at day 7. Levels of serum albumin and total protein, markers of vascular leakage, were markedly decreased beginning on day 4 and remained at these levels through the course of infection.
Coagulation Parameters
Prothrombin times (PTs) began to increase beginning on day 3 and continued to increase throughout the course of disease, whereas activated partial thromboplastin times (APTTs) did not increase until late in the disease course, on day 7. Beginning on day 2, gradual decreases in thrombin times (TTs) paralleled increases in fibrinogen content until terminal collection, when a sharp decrease was noted. Circulating protein C activity, as well as tissue factor levels, were decreased; however, plasminogen activator inhibitor-1, von Willebrand factor, and thrombin activatable fibrinolysis inhibitor levels were markedly increased, beginning on days 3, 5, and 6, respectively. Levels of bradykinin gradually increased to concentrations approximately 7-fold higher than those in controls late in disease ( Figure 4A ). No remarkable changes in circulating levels of T-TM, tPA, uPA, TFPI, or prekallikrein were detected.
Circulating Eicosanoid Content, Cytokine Levels, and Nitric Oxide Production
Circulating eicosanoid content of cysteinyl leukotrienes and thromboxane B2 gradually increased by 2-and 5-fold, respectively, whereas prostacyclin production peaked on day 4, at levels 14-fold higher than those for controls, and then remained elevated until death. Levels of hallmark markers of EHF-associated inflammation (ie, transforming growth factor β, tumor necrosis factor α, interleukin 6, and nitric oxide) were increased beginning on day 5 of disease [22] [23] [24] [25] . The level of HMGB-1, a marker associated with severe sepsis and disseminated intravascular coagulation, was also elevated late in disease (Supplementary Figure 2) [26, 27] .
DISCUSSION
With no licensed filovirus countermeasures currently available, the severity of the current ZEBOV outbreak in West Africa has revealed a dire need to rapidly screen candidate vaccines and therapeutics prior to their use in humans. The development of rodent models that closely reproduce EHF processes (ie, fever, diarrhea, weight loss, coagulopathies, vascular leak, pathologic lesions, and marked immune derangement similar to sepsis) while conferring predictive value for subsequent testing of these medical countermeasures in NHPs and humans offers an ethical alternative to screening for these materials in primates. An outbred rodent model has several advantages over inbred systems, the most important of which negates the altered immune responsiveness of inbred alternatives, which may provide increased testing stringency by inducing responses to infections more reflective of those in NHP and humans. Unique to the guinea pig is its larger size and circulating blood volume, relative to most other rodent models, which may be better accommodate the increased biological sampling and dosing necessary for optimizing therapeutic and vaccine development, an issue often problematic in smaller rodents. Here, we demonstrate hallmark features of EHF in outbred guinea pigs, including fever, weight loss, and infection of mononuclear/dendritiform cells early in the disease course, followed by striking splenic and hepatic pathology, lymphocyte apoptosis, neutrophilia, thrombocytopenia, and marked granulocytosis. Alterations from normal serum biochemistry characteristics also mirrored those in NHP and human disease, specifically with respect to marked increases in liver-associated enzyme levels and marked hypoalbuminemia. We provide multiple points of evidence to demonstrate severe coagulopathy in this outbred, small-animal model, including increased PT and APTT, decreased TT, decreased protein C activity, marked fibrinogen deregulation, increased circulating prostacyclin, thromboxane, vWF, and PAI-1 levels, and deposition of fibrin in tissues, all of which parallel that of NHPs and humans [28] [29] [30] [31] [32] [33] [34] . Although decreased levels of serum tissue factor were recorded here, we have yet to clarify whether levels are elevated in tissues, as previously documented in NHPs [21] . Additionally, we used this model to explore EHF-associated pathology and provide evidence for abrogation of proinflammatory lipid production, kinin-kallikrein, and fibrinolytic systems, as supported by increased levels of circulating leukotrienes, bradykinin, and TAFI, respectively.
Multiple changes in the genetic sequence were detected, which resulted in subsequent amino acid changes. Although we detected a mutation previously reported to be a virulence determinant in VP24, we cannot rule out whether the remaining changes in amino acid sequence may have contributed to virulence in outbred guinea pigs [20] . The changes in the gene encoding glycoprotein are of great interest, as this gene is not only relevant to receptor specificity and immune detection, it is also responsible for producing soluble forms previously identified as possible virulence determinants [35] [36] [37] [38] [39] [40] . With the availability of a reversegenetics systems for ZEBOV, these and related questions are now within reach and are targeted for future studies [20, 37, 41, 42] .
Despite the few differences from disease severity in humans and NHPs, the outbred Hartley strain guinea pig model presented here represents a robust, accessible, and broadly reflective rodent model of EHF for the study of comparative pathogenesis and development and initial screening of biomedical countermeasures against ZEBOV.
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